Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.37 |
| ▸ | ESR1 | P03372 | 13/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478864 | 1.00 | ESR2 (0.37) | ESR2ESR1IDO1JAK2JAK1 | |
| SCHEMBL16637189 | 0.81 | IDO1 (0.38) | ESR2ESR1IDO1TRPA1 | |
| SCHEMBL21542750 | 0.80 | IDO1 (0.37) | ESR2ESR1IDO1JAK2JAK1 | |
| SCHEMBL20315160 | 0.78 | IDO1 (0.37) | ESR2ESR1IDO1TRPA1MAP4K1 | |
| SCHEMBL31624902 | 0.78 | BRD4 (0.39) | IDO1TRPA1MAP4K1 | |
| SCHEMBL14663113 | 0.78 | TRPA1 (0.37) | ESR2ESR1IDO1TRPA1 | |
| SCHEMBL15186949 | 0.77 | LPL (0.33) | — | |
| SCHEMBL28782096 | 0.77 | AXL (0.50) | ESR2ESR1IDO1TRPA1 | |
| SCHEMBL21653719 | 0.71 | NOS1 (0.39) | ESR2ESR1IDO1TRPA1 | |
| SCHEMBL25230509 | 0.71 | TRPA1 (0.42) | ESR2ESR1IDO1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ESR2 1348/4885ESR1 2484/4885IDO1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.